<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03690076</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-408</org_study_id>
    <nct_id>NCT03690076</nct_id>
  </id_info>
  <brief_title>Human Cardiac Mitochondria in Acute Endocarditis and Obesity</brief_title>
  <acronym>MITHOM</acronym>
  <official_title>Development of the Purification of Human Cardiac Mitochondria, Characterization of These Organelles and Validation of the Model in Acute Endocarditis and Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Recherche Agronomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Clermont-Auvergne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Auvergne/Rh√¥ne-Alpes area</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart and Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data about human cardiac mitochondria are cruelly lacking in the literature. However, damages
      of the activity of these organelles are often the source of abnormal cardiac function in
      several pathologies. The purpose of this study is to develop a model of purified human
      cardiac mitochondria, to verify the purity of these organelles and to validate the
      authenticity of their function in acute endocarditis and obesity, two situations known to
      alter their activity. Animal studies have shown that microbial infection reduced
      mitochondrial metabolism whereas obesity increases it. The investigator's hypotheses are the
      following: 1) acute endocarditis, a form of cardiac microbial infection, reduces the function
      of human cardiac mitochondria; 2) obesity (body mass index &gt; 30) activates the metabolism of
      human cardiac mitochondria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3 groups of patients:

        -  Controls: patients with normal weight (23 &lt; BMI &lt; 27) operated for myocardial
           revascularization by bypass surgery, without infarction, or for valve pathologies
           without endocarditis

        -  Endocarditis: patients with normal weight (23 &lt; BMI &lt; 27) carriers of endocarditis with
           surgery indication

        -  Obese: obese patients (BMI &gt; 30) operated for myocardial revascularization by bypass
           surgery, without infarction, or for valve pathologies without endocarditis

      Comparisons studied:

        -  Controls vs. endocarditis

        -  Controls vs. obese patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mitochondrial function</measure>
    <time_frame>at day 1 (Moment of the surgery)</time_frame>
    <description>Measurement of oxidative phosphorylation and reactive oxygen species release in isolated human cardiac mitochondria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>walk test</measure>
    <time_frame>at the moment of inclusion in the study (day (-10-5)) and of the end of hospitalization (day +7+10)</time_frame>
    <description>6-minutes walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition</measure>
    <time_frame>1 day before the surgery</time_frame>
    <description>determination of lean masses by impedance-metry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram : Detections of the rates in events per min of arrhythmias</measure>
    <time_frame>at days (-10-5), (+7+10), (+30) and (+90)</time_frame>
    <description>Detections of the rates in events per min of arrhythmias (existence of P wave followed by a QRS complex) and atrio-ventricular blocks in all the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Membrane lipid composition</measure>
    <time_frame>at day 1 (at the day of surgery)</time_frame>
    <description>Fatty acid composition of plasma lipids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of oxidative stress in the plasma</measure>
    <time_frame>at days (0) and (+30) for the plasma and day (0) for the myocardium</time_frame>
    <description>Markers of the oxidative stress in the plasma (amounts of thiol groups and TBARS, activities of SOD, catalase, glutathione peroxidase, ratio between the amounts of GSH and GSSG) and in the myocardium (whole myocardium: ratio between the activities of aconitase and fumarase, amount of protein carbonylation; isolated mitochondria: amount of nitrosylated proteins)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of inflammation cytokines in the plasma</measure>
    <time_frame>at days (-10-5), (0), (+1), (+2), (+7) and (+90)</time_frame>
    <description>Inflammatory cytokines in the plasma (IL-6, IL-1b, TNF-a, fibrinogen, CRP and pro-calcitonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Semi-quantitative analysis of the amounts of approximatively 6000 molecules in the plasma by metabolomic and lipidomic techniques</measure>
    <time_frame>at days (0) and (+30)</time_frame>
    <description>Studies performed in the plasma by a U.S. private society (Metabolon)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>at day (+30)</time_frame>
    <description>Exercise testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient follow-up during the hospital stay</measure>
    <time_frame>morbi-mortality at day (+90)</time_frame>
    <description>quantity of time (h) spent by the patient during the stay in reanimation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbi-mortality</measure>
    <time_frame>measurement during the post-operative 90 days</time_frame>
    <description>rates of deaths and complications (cardiac, renal, hepatic, etc.) during the 90 days following the surgery for all the patients</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Obesity</condition>
  <condition>Endocarditis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>patients with normal weight (23 &lt; BMI &lt; 27) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endocarditis</arm_group_label>
    <description>patients with normal weight (23 &lt; BMI &lt; 27) carriers of endocarditis with surgery indication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese</arm_group_label>
    <description>obese patients (BMI &gt; 30 with waist to hip ratio &gt; or = 1 in men and 0.85 in women) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Endocarditis</intervention_name>
    <description>Comparison : Endocarditis vs. control</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Endocarditis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Obese vs. control</intervention_name>
    <description>Comparisons : Obese vs. control</description>
    <arm_group_label>Obese</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For the controls : adult patients with normal body weight (23 &lt; BMI &lt; 27)
             necessitating a cardiac surgery with sternotomy and extracorporeal circulation for
             myocardial revascularization or valve replacement

          -  For endocarditis : adult patients with normal body weight (23 &lt; BMI &lt; 27) and
             endocarditis of bacterial origin necessitating a cardiac surgery with sternotomy and
             extracorporeal circulation in order to cure a major valve regurgitation or vegetation
             with higher size than 15 mm with embolic risk

          -  For obese patients: adult patients with high body weight (BMI &gt; 30 and waist to hip
             ration &gt; or = 1 for men and 0.85 for women) necessitating a cardiac surgery with
             sternotomy and extracorporeal circulation for myocardial revascularization or valve
             replacement

        For all the patients:

          -  Ability to furnish an enlightened agreement

          -  Menbership of the French social security insurance

        Exclusion Criteria:

          -  Criteria linked to the surgery:

          -  Surgery of pressing emergency

          -  Aortic dissection

          -  Redux surgery

        Criteria linked to the patient:

          -  Protocol refusal

          -  Protected adult patients

          -  Previous psychiatric pathology including known addiction states

          -  Physical or intellectual inability

          -  Preexisting pathologies such as respiratory failure

          -  Cardiac failure (ejection fraction &lt; 30% pulmonary hypertenstion &gt; 80 mmHg); aortic
             counterpulsation; pre-operatory cardiogenic shock

          -  Severe acute or chronic renal failure with creatinine clearance &lt; 40 ml/min

          -  Inherited dyslipidemia

          -  Previous cardiac or thoracic surgery with pericardium opening

          -  Severe hepatic failure and severe chronic hepatic pathologies

          -  Evolving neoplasia

          -  Patients with long course corticoid treatment and with inflammatory diseases

          -  Patients with double anti-platelet treatment not stopped 48h before the surgery

          -  Protected people not involved in the study: pregnant women, nursing women,
             guardianship, deprived of liberty,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kasra AZARNOUSH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise LACLAUTRE</last_name>
    <phone>0473754963</phone>
    <email>drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lise LACLAUTRE</last_name>
      <email>drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Kasra AZARNOUSH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas COMBARET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc DEMAISON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibault LEGER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Val√©rie BATEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno PEREIRA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Mourmoura E, Rigaudi√®re JP, Couturier K, Hininger I, Laillet B, Malpuech-Brug√®re C, Azarnoush K, Demaison L. Long-term abdominal adiposity activates several parameters of cardiac energy function. J Physiol Biochem. 2016 Sep;72(3):525-37. doi: 10.1007/s13105-015-0427-7. Epub 2015 Aug 10.</citation>
    <PMID>26255304</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart</keyword>
  <keyword>Mitochondria</keyword>
  <keyword>Obesity</keyword>
  <keyword>Endocarditis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

